Sandra C. Quinn, Ph.D., and Michele P. Andrasik, Ph.D.
doi : 10.1056/NEJMp2103104
N Engl J Med 2021; 385:97-100
Jillian L. Goldfarb, Ph.D., Sarah Kreps, Ph.D., John S. Brownstein, Ph.D., and Douglas L. Kriner, Ph.D.
doi : 10.1056/NEJMp2104527
N Engl J Med 2021; 385:101-103
Joel D. Howell, M.D., Ph.D.
doi : 10.1056/NEJMp2033374
N Engl J Med 2021; 385:104-105
Jan A. Deprest, M.D., Ph.D., Kypros H. Nicolaides, M.D., Alexandra Benachi, M.D., Ph.D., Eduard Gratacos, M.D., Ph.D., Greg Ryan, M.D., Nicola Persico, M.D., Ph.D., Haruhiko Sago, M.D., Ph.D., Anthony Johnson, M.D., Miros?aw Wielgo?, M.D., Ph.D., Christoph Berg, M.D., Ph.D., Ben Van Calster, Ph.D., and Francesca M. Russo, M.D., Ph.D. for the TOTAL Trial for Severe Hypoplasia Investigators*
doi : 10.1056/NEJMoa2027030
N Engl J Med 2021; 385:107-118
Observational studies have shown that fetoscopic endoluminal tracheal occlusion (FETO) has been associated with increased survival among infants with severe pulmonary hypoplasia due to isolated congenital diaphragmatic hernia on the left side, but data from randomized trials are lacking.
Jan A. Deprest, M.D., Ph.D., Alexandra Benachi, M.D., Ph.D., Eduard Gratacos, M.D., Ph.D., Kypros H. Nicolaides, M.D., Christoph Berg, M.D., Ph.D., Nicola Persico, M.D., Ph.D., Michael Belfort, M.D., Ph.D., Glenn J. Gardener, M.D., Ph.D., Yves Ville, M.D., Ph.D., Anthony Johnson, M.D., Francesco Morini, M.D., Ph.D., Miros?aw Wielgo?, M.D., Ph.D., et al., for the TOTAL Trial for Moderate Hypoplasia Investigators*
doi : 10.1056/NEJMoa2026983
N Engl J Med 2021; 385:119-129
Fetoscopic endoluminal tracheal occlusion (FETO) has been associated with increased postnatal survival among infants with severe pulmonary hypoplasia due to isolated congenital diaphragmatic hernia on the left side, but data are lacking to inform its effects in infants with moderate disease.
Richard B. Warren, M.D., Ph.D., Andrew Blauvelt, M.D., Jerry Bagel, M.D., Kim A. Papp, M.D., Ph.D., Paul Yamauchi, M.D., Ph.D., April Armstrong, M.D., M.P.H., Richard G. Langley, M.D., Veerle Vanvoorden, M.Sc., Dirk De Cuyper, M.D., Christopher Cioffi, Ph.D., Luke Peterson, M.S., Nancy Cross, M.D., and Kristian Reich, M.D., Ph.D.
doi : 10.1056/NEJMoa2102388
N Engl J Med 2021; 385:130-141
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients with moderate-to-severe plaque psoriasis have not been extensively examined.
Kristian Reich, M.D., Ph.D., Richard B. Warren, M.D., Ph.D., Mark Lebwohl, M.D., Melinda Gooderham, M.D., Bruce Strober, M.D., Ph.D., Richard G. Langley, M.D., Carle Paul, M.D., Ph.D., Dirk De Cuyper, M.D., Veerle Vanvoorden, M.Sc., Cynthia Madden, M.D., Christopher Cioffi, Ph.D., Luke Peterson, M.S., and Andrew Blauvelt, M.D.
doi : 10.1056/NEJMoa2102383
N Engl J Med 2021; 385:142-152
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients with moderate-to-severe plaque psoriasis have not been extensively examined.
Julie R. Ingelfinger, M.D.
doi : 10.1056/NEJMra1604481
N Engl J Med 2021; 385:153-163
Sarah E. Goglin, M.D., and Mary E. Margaretten, M.D., M.A.S.
doi : 10.1056/NEJMicm2029589
N Engl J Med 2021; 385:164
Xue Feng, M.D., and Hong Qi, M.D.
doi : 10.1056/NEJMicm1913478
N Engl J Med 2021; 385:e5
Vikram Khurana, M.B., B.S., Ph.D., Claudio M. de Gusmao, M.D., McKinley Glover, M.D., and Jeffrey Helgager, M.D., Ph.D.
doi : 10.1056/NEJMcpc2004992
N Engl J Med 2021; 385:165-175
F. Sessions Cole, M.D.
doi : 10.1056/NEJMe2107446
N Engl J Med 2021; 385:177-178
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2111369
N Engl J Med 2021; 385:e15
Philip R. Krause, M.D., Thomas R. Fleming, Ph.D., Ira M. Longini, Ph.D., Richard Peto, F.R.S., Sylvie Briand, M.D., David L. Heymann, M.D., Valerie Beral, F.R.C.P., Matthew D. Snape, M.D., Helen Rees, M.R.C.G.P., Alba-Maria Ropero, B.Sc., Ran D. Balicer, M.D., Jakob P. Cramer, M.D., et al.
doi : 10.1056/NEJMsr2105280
N Engl J Med 2021; 385:179-186
Viral variants of concern may emerge with dangerous resistance to the immunity generated by the current vaccines to prevent coronavirus disease 2019 (Covid-19). Moreover, if some variants of concern have increased transmissibility or virulence, the importance of efficient public health measures and vaccination programs will increase. The global response must be both timely and science based.
doi : 10.1056/NEJMc2104974
N Engl J Med 2021; 385:187-189
doi : 10.1056/NEJMc2034981
N Engl J Med 2021; 385:189-191
doi : 10.1056/NEJMc2106921
N Engl J Med 2021; 385:e6
doi : 10.1056/NEJMc2107808
N Engl J Med 2021; 385:e7
doi : 10.1056/NEJMc2106004
N Engl J Med 2021; 385:e8
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟